Polycystic ovarian syndrome. A form of the metabolic syndrome

被引：0

作者：

Tauchert S. ^{[1
]}

Schröder A.K. ^{[1
]}

Ortmann O. ^{[2
]}

Diedrich K. ^{[1
]}

Weiss J.M. ^{[1
,3
]}

机构：

[1] Klin. F Frauenheilkunde/Geburtshilfe, Univ. Klin. Schleswig-Holstein, Campus Lübeck, Lübeck

[2] Klin. F Frauenheilkunde/Geburtshilfe, Caritas-Krankenhaus St. Josef, Universität Regensburg

[3] Klin. F Frauenheilkunde/Geburtshilfe, Univ. Klin. Schleswig-Holstein, Campus Lübeck, 23538 Lübeck

来源：

Der Gynäkologe | 2004年 / 37卷 / 8期

关键词：

Change of lifestyle; Insulin resistance; Metabolic syndrome; Polycystic ovarian syndrome;

D O I：

10.1007/s00129-004-1563-2

中图分类号：

学科分类号：

摘要：

Polycystic ovarian syndrome, with a prevalence of 5-10% the most common endocrinopathy in women of reproductive age, is more than a cosmetic or fertility problem. Due to its long-term consequences it poses a severe health problem. As insulin resistance is the core pathophysiology of PCOS it is associated with the metabolic syndrome (diabetes mellitus type II, dyslipidemia, hypertension, and atherosclerosis). The risk of myocardial infarction, stroke, or peripheral arterial occlusion is increased. In pregnant PCOS women the rate of spontaneous abortions as well as the risk of developing gestational diabetes is higher. In the treatment of PCOS the collaboration of gynecology and internal medicine is necessary. A change of lifestyle with healthy food and more physical exercise as well as the use of oral antidiabetic drugs are discussed.

引用

页码：681 / 685

页数：4

共 29 条

[1]

Achard C., Thiers J., Le virilisme pilaire et son association à l'insuffisance glycolytique (diabete des femmes a barbe), Bull Acad Natl Med, 86, pp. 66-71, (1921)

[2]

Book C.B., Dunaif A., Selective insulin resistance in the polycystic ovary syndrome, J Clin Endocrinol Metab, 84, pp. 3110-3116, (1999)

[3]

Boulman N., Levy Y., Leiba R., Et al., Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease, J Clin Endocrinol Metab, 89, pp. 2160-2165, (2004)

[4]

Carmina E., Lobo R.A., Polycystic ovary syndrome (PCOS): Arguably the most common endocrinopathy is associated with significant morbidity in women, J Clin Endocrinol Metab, 84, pp. 1897-1899, (2001)

[5]

Conn J.J., Jacobs H.S., Conway G.S., The prevalence of polycystic ovaries in women with type 2 diabetes mellitus, Clin Endocrinol (Oxf), 37, pp. 119-125, (2000)

[6]

Dahlgren E., Janson P.O., Johannsson S., Lapidus L., Polycystic ovary syndrome and risk for myocardial infarcation. Evaluation from a risk factor model based on a prospective population based study of women, Acta Obstet Gynecol Scand, 71, pp. 599-603, (1992)

[7]

Dunaif A., Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis, Endocr Rev, 18, pp. 774-800, (1997)

[8]

Dunaif A., Segal K.R., Futterweit W., Dobrjansky A., Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome, Diabetes, 38, pp. 1165-1174, (1989)

[9]

Ehrmann D.A., Sturis J., Byrne M.M., Et al., Insulin secretory defects in polycystic ovary syndrome, J Clin Invest, 96, pp. 520-527, (1995)

[10]

Ehrmann D.A., Barnes R.B., Rosenfield R.L., Et al., Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome, Diabetes Care, 22, pp. 141-146, (1999)

← 1 2 3 →